Sanofi acquiring Dynavax for $2.2bn to expand adult vaccine portfolio
Listed global pharmaceutical company Sanofi has agreed to acquire infectious diseases vaccine specialist Dynavax Technologies for $2.2bn. The transaction marks a strategic push to dominate the underpenetrated adult vaccination market and diversify beyond a flu-heavy portfolio. The deal, priced at a 39% premium over Dynavax’s closing price on December 23, 2025, brings Sanofi immediate access to HEPLISAV-B, the only two-dose…